AI Magazine Issue 3 2018

Acquisition International - Issue 3 2018 9 Transforming the Pharmaceutical Landscape thirst for diversity, our respect for traditions and our aim to be a global leading company.” Ultimately, discussing the future of Sintetica, Pasquale is delighted to explain that a strategy for the firm going forwards has been approved. There are clearly exciting times ahead for Sintetica, with a plan set for the company to capitalise on its strong growth in the times ahead. “Moving forwards, the strategic plan ‘Strategia 2021’ has been approved by the board. This plan calls for the international commercial diffusion of the innovation as main leverage to grow in the next future. Global Division is focusing on high speed robust partner selection and affiliation in each and every country of the world, offering a dynamic portfolio of selected branded medicines, developed to answer unmet clinical needs, to build sustainable and long-lasting alliances. “Lastly, we will executive projects to improve the industrial sites which are manufacturing capacity and pharmaceutical and clinical pipeline developments that are major pillars to sustain the midterm strong growth.”